Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 22, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

March 26, 2024

Conditions
End-stage Renal DiseaseKidney Failure, Chronic
Interventions
DEVICE

HAVG graft implantation

Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.

Trial Locations (3)

20-081

Department of Vascular Surgery and Angiology at the Medical University Lublin, Lublin

02-097

Independent Public Central Clinical Hospital in Warsaw; Department of General, Vascular and Transplant Surgery, Warsaw

51-124

Regional Specialist Hospital in Wroclaw; Clinic of Vascular Surgery, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

FGK Clinical Research GmbH

INDUSTRY

lead

Humacyte, Inc.

INDUSTRY